Satellos Bioscience (MSCLF) Price & Analysis

Compare

23 Followers

MSCLF Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.33 - $0.94

Previous CloseN/A

Volume2.00K

Average Volume (3M)102.64K

Market Cap

$80.01M

Enterprise Value$37.61M

Total Cash (Recent Filing)$69.85M

Total Debt (Recent Filing)C$0.00

Price to Earnings (P/E)―

Beta0.67

Next Earnings

Sep 01, 2025

EPS Estimate

-0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding176,305,360

10 Day Avg. Volume93,855

30 Day Avg. Volume102,644

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)1.37

Price to Sales (P/S)0.00

P/FCF Ratio-3.81

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$0.91

Price Target Upside93.62% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Satellos Bioscience News

PremiumCompany Announcements

Satellos Bioscience Reports Shareholder Meeting Outcomes and Strategic Approvals

20d ago

PremiumCompany Announcements

Satellos Bioscience to Engage with Duchenne Community at PPMD Conference

23d ago

PremiumCompany Announcements

Satellos Bioscience Reports Promising Phase 1b Trial Results for DMD Treatment

2M ago

PremiumCompany Announcements

Satellos Bioscience Advances DMD Drug Trials with Positive Financial Outlook

2M ago

PremiumCompany Announcements

Satellos Bioscience to Present at CureDuchenne FUTURES Conference

2M ago

PremiumCompany Announcements

Satellos Bioscience to Present at Healthcare Investor Conference

2M ago

PremiumCompany Announcements

Satellos Bioscience to Engage with Investors at April Conferences

3M ago

PremiumRatings

Satellos Bioscience: Buy Rating Backed by Promising Clinical Progress and Robust Financial Position

3M ago

See All MSCLF News

See All News >

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe company has made significant progress, well positioning itself for the next value inflection point.

Drug SafetyPhase 1a data demonstrated that SAT-3247 was safe and well-tolerated across multiple dosage levels.

Bears Say

Financial PerformanceThe company reported no revenue, in line with the consensus estimate, and a net loss.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

22.30% Insiders

0.66% Mutual Funds

― Other Institutional Investors

77.04% Public Companies and

Individual Investors

Detailed Ownership Overview >

MSCLF FAQ

What was Satellos Bioscience’s price range in the past 12 months?

Satellos Bioscience lowest stock price was $0.33 and its highest was $0.94 in the past 12 months.

What is Satellos Bioscience’s market cap?

Satellos Bioscience’s market cap is $80.01M.

When is Satellos Bioscience’s upcoming earnings report date?

Satellos Bioscience’s upcoming earnings report date is Sep 01, 2025 which is in 54 days.

How were Satellos Bioscience’s earnings last quarter?

Satellos Bioscience released its earnings results on May 13, 2025. The company reported -$0.041 earnings per share for the quarter, missing the consensus estimate of -$0.033 by -$0.008.

Is Satellos Bioscience overvalued?

According to Wall Street analysts Satellos Bioscience’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Satellos Bioscience pay dividends?

Satellos Bioscience does not currently pay dividends.

What is Satellos Bioscience’s EPS estimate?

Satellos Bioscience’s EPS estimate is -0.02.

How many shares outstanding does Satellos Bioscience have?

Satellos Bioscience has 176,305,360 shares outstanding.

What happened to Satellos Bioscience’s price movement after its last earnings report?

Satellos Bioscience reported an EPS of -$0.041 in its last earnings report, missing expectations of -$0.033. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Satellos Bioscience?

Currently, no hedge funds are holding shares in MSCLF

Satellos Bioscience Stock Smart Score

Underperform

Fundamentals

Return on Equity

-64.18%

Trailing 12-Months

Asset Growth

56.95%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Satellos Bioscience

Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

MSCLF Stock 12 Month Forecast

Average Price Target

$0.91

▲(93.62%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","-1":"-$1","-0.5":"-$0.5","0.5":"$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.91499,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$0.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.91,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.91499,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.91</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Aug<br/>2024","9":"Nov<br/>2024","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.46,0.4949992307692308,0.5299984615384615,0.5649976923076924,0.5999969230769231,0.6349961538461539,0.6699953846153847,0.7049946153846154,0.7399938461538462,0.774993076923077,0.8099923076923077,0.8449915384615385,0.8799907692307692,{"y":0.91499,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.46,0.4946153846153846,0.5292307692307693,0.5638461538461539,0.5984615384615385,0.6330769230769231,0.6676923076923077,0.7023076923076923,0.736923076923077,0.7715384615384615,0.8061538461538462,0.8407692307692308,0.8753846153846154,{"y":0.91,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.46,0.4949992307692308,0.5299984615384615,0.5649976923076924,0.5999969230769231,0.6349961538461539,0.6699953846153847,0.7049946153846154,0.7399938461538462,0.774993076923077,0.8099923076923077,0.8449915384615385,0.8799907692307692,{"y":0.91499,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.33,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.38,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.51,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.44,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.44,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.41,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.34,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.4,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.35,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.62,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.46,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >